having huge turnover on the ground that it is not in WHO list;

(d) whether it is a fact that Glipiside, Catopril and Oxyfedrine are exempted from price control inspite of the fact that annual sales turn over of each is more than Rupees Fifty lacs; and

(e) what steps are being taken to remove all these anomalies and discrepencies and by when these would be removed?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) and (b) Sales turnover of formulations is not monitored.

(c) to (e) The Committee recommended retention of these drugs under price control due to concentration in the formulation market by 2 companies in the case Cyproheptadine and very high concentration of formulation market by one company in the case of Diphenoxylate. The drugs referred to in part (d) of the question were exempted from price control under DPCO, 1987 on the basis of recommendations contained in the first report of the Kelkar Committee.

Recommendation of Kelkar Committee

2452. SHRI P. N. SUKUL: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that the recommendations of Kelkar Committee has been examined by his Ministry at all levels;

(b) if so, whether his Ministry has found any anomaly in the recommendations;

(c) if so, what are the details thereof;

(d) whether it is a fact that exclusion of polymixin B Sulphate, Glybenclamide M thdilaxine, Diphenhydramine Hcl. Triprolidine are wrong and contrary to the criteria adopted;

(e) whether it is also a fact that a number of representations have also been received from Members of Parliament against the wrong exclusion of these drugs; and

(f) if so, what steps are being taken to appoint a Committee of Members of Parliament to unearth the truth?

THE MINISTER OF STATE IN THE MINISTRY OF PARLIAMENTARY AFFAIRS AND THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS IN THE MINISTRY OF INDUSTRY (SHRI P. NAMGYAL): (a) to (e) Government, after careful consideration, have taken decision on all the major recommendations of the Kelkar Committee.

(f) There is no proposal to appoint any other Committee in this regard.

DPEA liability of IDPL and HAL

2453. SHRI DHULESHWAR MEENA : Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 138 given in the Rajya Sabha on the 24th April, 1989 and state:

(a) the names of drugs, quantity of each and difference between the price fixed and price realised which resulted in IDPL liability on the DPEA of Rs. 292·88 lakhs during 1987-88 and rupees 115 lakhs during 1988-89;

(b) what is the total amount recovered by his Ministry under DPEA from the inception of Drugs Price Control Order 1979 and what are the details of each source;

(c) what is the total amount paid to IDPL and HAL respectively from the DPEA;

(d) what are the names of drugs, rate and quantity on which the